# Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

> **NCT04486911** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 89 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib maleate, SHR6390, letrozole

## Key facts

- **NCT ID:** NCT04486911
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-27
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486911, "Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04486911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*